Introduction
Peripheral T-cell lymphomas (PTCLs) comprise a heterogeneous group of indolent and aggressive T-cell lymphomas that confer a variable prognosis [1] . T-cell receptor gammadelta (TCRcδ) PTCLs are characterized based on their expression of cδ glycoproteins within the TCR complex rather than more common alpha-beta (αβ) glycoproteins identi ed in normal T-cells and in most T-cell neoplasms [2] . cδ T-cells are subdivided into Vδ1 and Vδ2 subtypes and have demonstrated capacity for cytotoxicity, memory, and antigen presentation [3] . Mature cδ PTCLs have no clear etiology to date and can be divided into three categories based on location: hepatosplenic (HSTLcδ), cutaneous (PCTCLcδ), and nonhepatosplenic/noncutaneous (NHNCcδ PTCL). HSTLcδ and PCTCLcδ both carry a similarly dismal prognosis [4] .
NHNCcδ PTCL represents a miscellaneous group of unrelated T-cell lymphomas of which only isolated cases have been reported; thus, characterization remains limited. Reported sites of involvement include lymph nodes and mucosal sites (nasopharynx and intestine), as well as the larynx, thyroid, lung, breast, and testis [5] [6] [7] [8] . NHNCcδ subtypes of PTCLs generally behave more aggressively compared to αβ counterparts with an exception of cδ variant of T-cell large granular lymphocyte (LGL) leukemia [9] .
No cytogenetics ndings unique to NHNCcδ PTCL have been reported [10] . i7q, if detected, is not speci c to cδ PCTLs [11] . Gene sequencing of cδ PCTLs has demonstrated conservation of LGR4, C3AR1, and SCARF2 among all cδ PTCLs [12] . Notably, the NHNCcδ PTCLs had CCL19, MMP9, and UBD mutations, whereas HSTLcδ PCTLs did not. ese mutations were also strongly conserved in the αβ PTCLs studied. Although there is evidence that some variants of cδ PTCLs respond in vitro to aurora kinase inhibitors, among all PTCLs, those with TCRcδ have the worst prognoses [13] [14] [15] .
As opposed to PTCL, the expression of cδ TCR is relatively common in (up to 50%) in T-lymphoblastic leukemia/lymphoma (T-ALL). Clinical features are similar to those that express αβ TCR, and outcomes are comparable [8] . Here, we describe a case of transformation from T-ALL to NHNCcδ PTCL. Despite being rarely reported, we also report a second case of PTCL arising in a patient with prior T-ALL. Such transformation may carry important diagnostic and biological implications.
Case Presentations

Patient 1.
Patient 1 is a 31-year-old gentleman diagnosed with T-cell ALL after presenting with di use petechial rash, cervical lymphadenopathy, abdominal pain, and a WBC of 121 K/μL with 40% blasts (Figure 1 ). Cytogenetics showed 46, XY,add(13) (p11.2) [3] /46,XY [17] . No BCR/ABL was detected by FISH; CSF was uninvolved. T-ALL was CD4+/CD8+, CD2+, CD3+, CD5+ (dim), CD7+, and TdT (dim). He was treated with vincristine, daunorubicin, pegylated L-asparaginase, and prednisolone achieving complete remission (CR). He was referred for hematopoietic stem cell transplant three months later which was delayed due to chemotherapy complications. During this period, he received leucovorin and glucarpidase. Prior to the transplant, a bone marrow biopsy was negative, but revealed clonal TCR β and c gene rearrangements. In addition, CSF showed numerous LGLlike cells. e patient developed high grade fever and over one hundred erythematous plaques on his trunk, upper extremities, and lower extremities (Figure 2 ). Skin biopsy showed NHNCcδ PTCL ( Figure 3 ) as did staging bone marrow biopsy (Figure 4 ). e malignant cells demonstrated mature chromatin, LGL-like morphology with prominent azurophilic granules resembling those seen in patient 2's PTCL (see below).
ey coexpressed CD4, CD8, CD56, cytotoxic markers, and c-TCR. TdT was negative. Molecular studies of the PTCL demonstrated that both the T-ALL and PTCL shared identical clonal TCR rearrangement peaks for both TCR β and TCR c ( Table 1) .
Six months after initial CR, the patient was initiated on ICE therapy and intra-Ommaya reservoir methotrexate (later switched to intrathecal cytarabine). e skin lesions and CSF involvement initially resolved; however, he developed fevers, new generalized skin δc-PTCL, nodal/hepatic progression by radiology, and CSF recurrence consistent with progressive disease. Bone marrow transplant was deferred, and the patient was admitted for hyper-CVAD chemotherapy. However, the patient requested transfer despite the worsening condition. Current clinical status is unknown.
Patient 2.
Patient 2, deceased, was a 63-year-old Caucasian female with a past medical history signi cant for stage III invasive ductal carcinoma, ER/PR/HER2 negative, with 1 of 9 axillary lymph nodes positive for carcinoma, diagnosed at age 52. She underwent a left segmental mastectomy (lumpectomy) procedure with axillary lymph node dissection, radiation treatment, and 4 cycles of doxorubicin and cyclophosphamide chemotherapy. Other medical problems included hypertension, hyperlipidemia, herpes zoster, childhood rheumatic fever, menopause, and hypersensitivity pneumonitis.
She initially presented with a mediastinal mass, dyspnea, and pericardial and recurrent right-sided pleural e usions. Biopsy of the mediastinal mass revealed blasts with cyCD3+, TdT+, CD4+/8+, CD7+ ( Figure 5 ). TCR gamma gene rearrangement studies demonstrated clonal gene rearrangements.
e peripheral blood and bone marrow were also involved. She was treated with 18 cycles of hyper-CVAD followed by POMP maintenance for 18 months and remained in remission for nearly 4 years.
ereafter, she developed dyspnea, and radiographic imaging showed several simultaneous masses, including a 4.7 × 4.0 cm right atrial mass and a left ank mass, in addition to pleural e usions. Biopsy of the atrial mass was nondiagnostic showing myocardial and brous tissue. e chest wall ( ank) mass was biopsied showing involvement by PTCL ( Figure 6 ). Pleural uid analysis showed involvement by CD3+ large lymphoid cells with markedly irregular nuclear contours, cytoplasmic azurophilic granules, lacking TdT and CD7, and showing positivity for CD8. Clonal TCR β and c gene rearrangements were detected. Staging bone marrow biopsy showed no evidence of T-ALL.
However, clonal TCR β and c gene rearrangements were detected with a possible similar peak to that detected in the pleural e usion sample (Table 2) . Shared identical clonal TCR peaks were not noted between T-ALL and PTCL specimens, but comparison is limited by the fact that TCR testing was performed in di erent labs and may have used disparate primer sets and analysis parameters. e patient later received 2 cycles of ESHAP resulting in partial response. However, PET scan showed SUV of 11 in the cardiac area. Romidepsin salvage chemotherapy was administered. e patient continued to have large pleural e usions with respiratory issues and eventually opted for hospice. She died 4 months after her presentation with PTCL and 50 months after her original diagnosis of T-cell ALL, at age 64.
Discussion
In both cases, there was relapse as PTCL manifested with skin involvement and an overt shift from blastic morphology to "LGL-like" mature T cells with ample cytoplasm and abundant azurophilic granules. Phenotypically, expression of immature markers such as TdT was lost in both cases. Both patients reasonably represent a novel phenomenon of clonal transformation from T-ALL to PTCL which has rarely been reported in the literature. In patient 1, there is clear evidence of a clonal relationship as demonstrated by identical monoclonal TCR peaks. Also, both PTCL and T-ALL cases demonstrated the relatively immature CD4+/CD8+ immunophenotype. HSTLcδ are often CD4-/CD8-, recapitulating normal cδ T cells, and less commonly C8+/CD4-is seen. In other cδ PTCLs, CD4+/CD8− phenotype may be observed perhaps deriving from a subset of normal cδ T cells that harbor this phenotype [8] . However, dual CD4+/CD8+ has not been typically reported and is di cult to explain [16] . A clonal relationship is less clear for patient 2. However, the genesis of an entirely new PTCL in a patient with established T-ALL would be unusual indeed. TCR gene rearrangements cannot be reliably compared between the original T-ALL and PTCL due to their performance in di ering laboratories.
Morphologically, cδ PTCLs are a heterogeneous group. However, in both our cases we nd a "LGL-like" morphology with large cells with ample cytoplasm containing cytoplasmic granules further supporting the notion that a common phenomenon may be at play in these two cases. Furthermore, SNP microarray performed on patient 2's PTCL showed clonal alterations in 95% of the cells, but clonal evolution was seen in 41-55% of the cells suggesting further that this represents a type of transformation. Furthermore, homozygous interstitial deletion 14q32.2 was detected which houses BCL11B. BCL11B encodes a transcription factor necessary for normal T-cell development and has been implicated in T-ALL pathogenesis [17] . Another line of evidence that supports the idea that these cases may represent a novel phenomenon is the detection of aberrations occurring at similar genetic loci in both cases. If this truly represents transformation, we must consider the pathophysiology of such conversion. It may be postulated that chemotherapy may have forced the original T-ALL cells to undergo some degree of maturation. However, the disparate chemotherapy regimens in both cases, lack of similar conversions in other patients treated with these typical chemotherapy regimens, and temporal distance of relapse in patient 2 (3-4 years) do not support this speculation. More likely, acquisition of additional mutations in T-cell di erentiation genes may have created a genetic context to allow for such transdi erentiation.
is is supported by SNP array analysis performed on patient 2's PTCL showing clonal evolution. Another possibility is that malignant clones of T-ALL and PTCL developed separately from a common precursor sharing an initial transforming event. Subsequently, T-cell ALL and PTCL could evolve secondary to additional and separate transforming events.
e transformation into more aggressive disease is a rare event in T-cell lineage-derived hematologic malignancies compared to B-cell neoplasms. A patient with cδ-variant of LGL leukemia who developed aggressive ALL-like disorder after about 20 years of an indolent course has previously been reported [16] . Interestingly, cytology of leukemic cells during aggressive phase of disease did not di er signi cantly from
LGLs assessed during indolent phase of disease. However,
LGLs of the aggressive leukemia revealed very high Ki-67 proliferation index of 80%, and SNP array showed multiple genetic abnormalities most probably implicated in the transformation.
is report supports our hypothesis that transformation in T-cell lymphomas/leukemia is a very rare event and that multiple acquired somatic mutations secondary to therapeutic or environmental factors likely facilitated the transformed phenotype.
Besides the pathophysiology, the clinical and biological nature of these transformed PTCLs can be considered challenging. Should these cases be considered "ALL-like" disorders given their putative clonal derivation from T-ALL or do they represent a new entity with unique biology? e second case was considered to be a new entity with unique biology, hence the aggressive, chemotherapy refractory course that resulted.
In summary, we report two cases of NHNC PTCL arising in patients with established diagnoses T-ALL which, in at least one case, is clonally related. is raises the possibility of a novel pathologic phenomenon with associated diagnostic and biological implications.
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